Payment overview · 2025
General Payments
$787.12
31 reported records · 13 companies
Healthcare provider profile · identity verified
Madineth Muy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE FOREST, CA · NPI 1992807721
Verified facts
What the public records show
CMS Open Payments records show Madineth Muy, M.D. received $787.12 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.08 | 21.4% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.27 | 15.4% | 5 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $99.78 | 12.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.67 | 10.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.45 | 6.7% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.75 | 5.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.47 | 5.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.94 | 5.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.04 | 5.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $28.18 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.64 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.38 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.47 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $787.12 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $141.75 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $100.70 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $99.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $81.67 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $81.67 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $81.67 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $52.45 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $52.45 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $42.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.04 | 2 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.33 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 50 |
| Lisinopril | Lisinopril | 148 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 41 |
| Simvastatin | Simvastatin | 108 | 29 |
| Alprazolam | Alprazolam | 105 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 30 |
| Sertraline Hcl | Sertraline Hcl | 92 | 28 |
| Metformin Hcl Er | Metformin Hcl | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 44 |
| Losartan Potassium | Losartan Potassium | 82 | 24 |
| Alendronate Sodium | Alendronate Sodium | 74 | 22 |
| Potassium Chloride | Potassium Chloride | 73 | 23 |
| Omeprazole | Omeprazole | 72 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 22 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Furosemide | Furosemide | 54 | 15 |
| Valsartan | Valsartan | 51 | 15 |
| Metformin Hcl | Metformin Hcl | 47 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 14 |
| Estradiol | Estradiol | 39 | 14 |
| Gabapentin | Gabapentin | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Atenolol | Atenolol | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 19 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 15 |
| Famotidine | Famotidine | 29 | 13 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Aciphex | Rabeprazole Sodium | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $787.12 · 31 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Da Vinci Surgical System, EDARBI, FARXIGA, GARDASIL 9, GEMTESA, HORIZANT, KISUNLA, M-M-R II, MOUNJARO, OTEZLA, PREVNAR 20, QUTENZA, REPATHA, SHINGRIX, WaveWriter Alpha Prime 16 | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error